Eurostars project:
BioRADT – Precision Biomarkers for Personalized Treatment in Rheumatoid Arthritis

Lipum AB (publ) and the Norwegian biotech company Age Labs AS have initiated BioRADT, a joint research project to develop biomarkers that can predict treatment response in patients with rheumatoid arthritis (RA). The project is co-funded by Eurostars, Vinnova, and the Research Council of Norway, and supports the growing field of personalized medicine for chronic inflammatory diseases. Eurostars is part of the European Partnership for Innovative SMEs with support from the European Union through Horizon Europe.

The aim is to identify proteomic and epigenetic biomarkers that indicate which patients are most likely to benefit from Lipum’s drug candidate SOL-116. This could lead to more effective, individualized treatment and improve outcomes in clinical trials.

With a total budget of approximately EUR 1.9 million, 50% of which is grant-funded, the three-year project will also contribute to the development of a companion diagnostic test, enabling targeted therapy and reducing unnecessary patient suffering.

Age Labs, based in Oslo, specializes in epigenetic analysis and predictive algorithms for early disease detection. Initial studies on Lipum’s target molecule, BSSL, show promising potential to meet the project’s goals.